EQT Life Sciences and Gimv Co-Lead €51 Million Series B for Exciva’s Alzheimer’s Therapy

Announced in a press release, EQT Life Sciences and Gimv have co-led a €51 million Series B financing round for Exciva, a clinical-stage biopharmaceutical company developing therapies for behavioral symptoms associated with Alzheimer’s disease.

The funding will support Exciva’s Phase 2 clinical trial of its lead candidate, Deraphan, which targets agitation linked to Alzheimer’s. The trial will take place across the European Union, the United States, and Canada. Additional investors include Fountain Healthcare Partners, LifeArc, Carma Fund, Modi Ventures, Andera Partners, and LBBW.

Deraphan combines two clinically validated compounds, one of which is a new chemical entity, and has shown encouraging safety and tolerability in Phase 1 trials. The company aims to deliver improved efficacy and safety compared to existing treatments, which are often limited by warnings or inconsistent results.

Following the investment, EQT Life Sciences will join Exciva’s board, represented by Philip Scheltens as a Director and Juliette Lee as an Observer.